| 1 |
35617514 | Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). | 2022 May 26 |
1 |
| 2 |
33099927 | Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells. | 2020 Jul-Aug |
1 |
| 3 |
29526823 | Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. | 2018 Jun |
2 |
| 4 |
29928418 | Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. | 2018 Jul |
4 |
| 5 |
29959144 | Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. | 2018 Oct 1 |
1 |
| 6 |
30172884 | Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation. | 2018 Dec |
1 |
| 7 |
28566331 | Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. | 2017 Jul 15 |
1 |
| 8 |
27287717 | IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. | 2016 Aug 1 |
4 |
| 9 |
25870145 | Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. | 2015 Jun 15 |
2 |
| 10 |
25959272 | EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. | 2015 Dec |
4 |
| 11 |
26622906 | Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells. | 2015 Oct |
2 |
| 12 |
24200969 | Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. | 2014 |
1 |
| 13 |
23588995 | MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands. | 2013 Jun |
5 |
| 14 |
22082529 | Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. | 2012 Mar |
5 |
| 15 |
21118963 | MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. | 2011 Jan 15 |
2 |
| 16 |
20103661 | Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. | 2010 Feb 1 |
1 |
| 17 |
19755509 | Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. | 2009 Sep |
1 |